Regentis Biomaterials Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	7.38	0.23	0.35	1.24	2.74
Cash & Short-Term Investments	7.38	0.23	0.35	1.24	2.74
Cash Growth	3121.83%	-33.62%	-72.18%	-54.81%	98.98%
Other Current Assets	0.24	0.25	0.02	0.48	0.37
Total Current Assets	7.62	0.48	0.36	1.72	3.12
Total Assets	7.62	0.48	0.36	1.72	3.12
Accounts Payable	0.27	0.25	0.35	0.21	0.31
Accrued Expenses	1.41	1.13	2.58	2.4	2.42
Short-Term Debt	1.2	4.95	0.21	6.47	6.08
Other Current Liabilities	-	0.16	-	0.69	0.79
Total Current Liabilities	2.87	6.49	3.14	2.61	2.72
Long-Term Debt	-	-	7.41	-	-
Other Long-Term Liabilities	-	-	0.62	-	-
Total Long-Term Liabilities	-	-	8.03	-	-
Total Liabilities	2.87	6.49	11.17	9.77	9.58
Additional Paid-in Capital	60.54	1.04	1.04	0.75	0.75
Retained Earnings	-55.79	-42.15	-46.95	-42.82	-41.23
Total Common Shareholders' Equity	4.74	-41.1	-45.91	-42.06	-40.48
Minority Interest	-	35.1	35.1	34.01	34.01
Shareholders' Equity	4.74	-6.01	-10.81	-8.05	-6.47
Total Liabilities & Equity	7.62	0.48	0.36	1.72	3.12

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q